Apple (AAPL) closed up 2% Thursday to $308.43. Overall option implied volatility of 36 is near its 26-week average, according to Track Data, suggesting non-directional price movement.

iShares NASDAQ Biotechnology Index (IBB) closed up 1.5% to $88.32. Overall option implied volatility of 21 is near its 26-week average according to Track Data, suggesting non-directional price movement

CBOE Volatility Index (VIX) is recently down 13.8% to 18.75, below its ten-day moving average of 19.66.

Options Update is by Stock Specialist Paul Foster of theflyonthewall.com.

Option traders appear to be setting up for a bullish move on ProLogis (PLD). Traders plowed into 1,067 new call option contracts -- 2.81 times the average volume -- on the stock on Thursday. And we know that traders were eager to get into this trade because 95% of the trades came in on the ask price.

ProLogis looks like it formed a bottom in early July and has since formed a higher low in August. The stock closed Thursday at $10.92, down 0.18% during the past month.

"I'm always looking for market leadership; right now, biotechnology stocks are moving up faster than most anything else," says Ron Rowland. In Money & Markets, he eyes biotech ETFs.

"Biotechnology is a fascinating sector, one that's made (and lost) a lot of money for millions of investors in recent decades. That's why, in my opinion, you should become familiar with this industry.

"Broadly speaking, it's the application of technology to biological materials - plants, animals and people.

"Nowadays a lot of biotechnology involves manipulating genetic material: The DNA that forms the basis for life. The goal is to produce new and useful substances that make life better and, of course, turn a profit along the way.

"Health care reform could mean opportunities for astute investors," says Brandon Clay in his Invest With an Edge.

Here, eyes two biotech ETFs that "should be on everyone's watch list." The advisor notes, "With health care on the front burner in Washington, these biotechnology ETFs may finally be ready to pop."

"Investors in health care should think outside the realm of traditional pharmaceutical companies and health insurers. Those sectors are each facing headwinds that make stock picking difficult.

"In addition, several big pharma companiesare desperate to reload their empty pipelines in the face of increased competition from generic drug makers.

One of the buzzwords that is currently in vogue in the investment community is biotechnology. This is a broad-based field that covers technological applications in any biological system, meaning humans, animals, agriculture, and medicines. This is a booming science and the investment field offers many opportunities for wealth accumulation.

If you don't want to spend countless hours trying to understand not just financials, but scientific and technical jargon that biotech companies harbor, exchange-traded funds (ETFs) may be the better choice for investing in the biotechnology industry.

An ETF is similar to buying a share of a company, but instead of getting one particular company you're investing in a bundle of companies within a particular field or specialty. It's a great way to invest in something you believe in while still hedging your bets and having a bit of diversity.